Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03865082
Title Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Idera Pharmaceuticals, Inc.

colorectal cancer

laryngeal squamous cell carcinoma

oropharynx cancer

hypopharynx cancer

oral squamous cell carcinoma


IMO-2125 + Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST